Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer recurring in patients who initially respond.

In a significant development for pancreatic cancer treatment, a phase 1 clinical trial has highlighted the potential of personalized mRNA vaccines to treat the deadly disease. This research comes at a critical time,

A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently approved vaccine for TB – which recently surpassed COVID-19 to once again become the deadliest infectious disease on Earth – the findings are a great step forward in the quest to combat humanity’s ancient foe.

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target and reduce malignant tumors. NBC News medical contributor Dr. Kavita Patel reports on the vaccine’s success against pancreatic cancer,

"It's really exciting, because when we talk about curing cancer, it's not really a single monolithic disease," he added. "There are probably hundreds of different targets for ever

As per a new study, the potential of mRNA vaccines offers a personalized treatment for patients with pancreatic cancer.